TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.79 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.90.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.99, a 90.16% decline year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $10.06.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $11.00.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $14.44, a 39.92% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $10.32, a 26.63% increase from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.15, a 20.49% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $10.25, a 42.48% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.79 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $3.90 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $14.44 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $17.14 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $17.04 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $10.32 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $0.86 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $0.86 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $0.99 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $8.15 10-K · filed 2024-03-06 | |||
| 2023-09-30 | $8.31 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $8.76 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $10.06 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $10.25 10-K · filed 2023-03-06 | |||
| 2021-12-31 | $17.82 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $15.88 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $17.44 10-K · filed 2020-02-27 | |||
| 2014-09-30 | $12.17 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $12.11 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $11.00 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |